Previous 10 | Next 10 |
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that Dr. Sean Ianchulev, Chairman, Chief Executive Officer a...
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will present an ePoster at the American Society of Cata...
Eyenovia, Inc. (EYEN) Q4 2021 Earnings Conference Call March 28, 2022 16:30 ET Company Participants Eric Ribner - Investor Relations Sean Ianchulev - Chairman, Chief Executive Officer and Chief Medical Officer Michael Rowe - Chief Operating Officer John Gandolfo - Chief Financial Officer Conf...
Eyenovia press release (NASDAQ:EYEN): Q4 GAAP EPS of $0.10 beats by $0.32. Revenue of $10M (+400.0% Y/Y). As of December 31, 2021, the Company’s cash and cash equivalents were approximately $27.3 million, including $7.9 million of restricted cash, compared to $28.4 million as of Decemb...
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022 Enrolled first patient in the Phase 3 VISION-2 study evaluating MicroLine as an on-demand treatment for improving near vision (presbyopia) Entered into a $15 million Securit...
CYCC, DNA, EGLX, EYEN, HNRG, IONQ, LIDR, MBII, PLAY, OTCQX:PLNHF, PROG, RSLS, THMO, WYY, XOS, ZEV For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, announced that the Company will release financial results for the fourth quarter and ful...
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced positive results from a research study conducted in collaboration with D...
Eyenovia (NASDAQ:EYEN) trades 2.3% down premarket after it entered into a securities purchase agreement with Armistice Capital Master Fund in an offering of 3M shares of its common stock pre-funded warrants to purchase up to 1.87M shares and common warrants to purchase up to 4.87M s...
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a Securities Purchase Agreement with A...
News, Short Squeeze, Breakout and More Instantly...
Collaboration to focus on the development of a formulation of Senju’s SJP-0035 for use with Eyenovia’s Optejet ® dispensing technology, following consultation with FDA Chronic dry eye estimated to be a $5 billion global addressable market NEW YORK, July 23, ...
Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for Eyenovia's launch of clobetasol propionate ophthalmic suspension, ...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current large...